1,334 Shares in Thermo Fisher Scientific Inc. (NYSE:TMO) Acquired by Wills Financial Group LLC

Key Points

• Wills Financial Group LLC acquired a new stake in Thermo Fisher Scientific, purchasing 1,334 shares valued at approximately $664,000 during the first quarter.
• The company's recent earnings report revealed a net income of $10.86 billion with earnings per share of $5.36, surpassing analysts' expectations.
• Thermo Fisher Scientific announced a quarterly dividend of $0.43 per share, set to be paid on October 15th, with a dividend yield of 0.4%.

Wills Financial Group LLC bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,334 shares of the medical research company's stock, valued at approximately $664,000.

Other large investors also recently made changes to their positions in the company. Capital World Investors increased its position in shares of Thermo Fisher Scientific by 1.1% in the fourth quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock worth $4,905,812,000 after purchasing an additional 104,343 shares during the period. Northern Trust Corp lifted its holdings in shares of Thermo Fisher Scientific by 13.2% during the fourth quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock worth $2,034,107,000 after purchasing an additional 455,004 shares during the period. T. Rowe Price Investment Management Inc. increased its stake in shares of Thermo Fisher Scientific by 86.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock valued at $1,604,338,000 after buying an additional 1,433,444 shares during the period. Pictet Asset Management Holding SA boosted its position in shares of Thermo Fisher Scientific by 7.2% during the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock valued at $1,432,816,000 after purchasing an additional 193,378 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Thermo Fisher Scientific by 11.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,420,949 shares of the medical research company's stock worth $1,259,450,000 after buying an additional 257,462 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

TMO has been the topic of several research reports. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective on the stock in a report on Friday, July 11th. Robert W. Baird increased their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Royal Bank Of Canada reduced their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Raymond James Financial reiterated an "outperform" rating and issued a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, UBS Group upped their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. Six equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $593.00.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Down 3.6%

Shares of TMO traded down $16.74 on Wednesday, hitting $449.68. 2,539,237 shares of the stock traded hands, compared to its average volume of 3,309,601. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The stock's 50 day moving average is $423.62 and its two-hundred day moving average is $465.77. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $169.80 billion, a P/E ratio of 26.01, a P/E/G ratio of 2.49 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company's quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the company posted $5.37 earnings per share. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.